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Background: Differential diagnosis between malignant follicular thyroid cancer (FTC) and benign follicular thyroid
adenoma (FTA) is a great challenge for even an experienced pathologist and requires special effort. Molecular
markers may potentially support a differential diagnosis between FTC and FTA in postoperative specimens. The
purpose of this study was to derive molecular support for differential post-operative diagnosis, in the form of a
simple multigene mRNA-based classifier that would differentiate between FTC and FTA tissue samples.
Methods: A molecular classifier was created based on a combined analysis of two microarray datasets
(using 66 thyroid samples). The performance of the classifier was assessed using an independent dataset
comprising 71 formalin-fixed paraffin-embedded (FFPE) samples (31 FTC and 40 FTA), which were analysed by
quantitative real-time PCR (qPCR). In addition, three other microarray datasets (62 samples) were used to confirm
the utility of the classifier.
Results: Five of 8 genes selected from training datasets (ELMO1, EMCN, ITIH5, KCNAB1, SLCO2A1) were amplified by
qPCR in FFPE material from an independent sample set. Three other genes did not amplify in FFPE material,
probably due to low abundance. All 5 analysed genes were downregulated in FTC compared to FTA. The sensitivity
and specificity of the 5-gene classifier tested on the FFPE dataset were 71% and 72%, respectively.
Conclusions: The proposed approach could support histopathological examination: 5-gene classifier may aid in
molecular discrimination between FTC and FTA in FFPE material.
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Discrimination between malignant follicular thyroid cancer
(FTC) and benign follicular thyroid adenoma (FTA) is
the most difficult aspect of thyroid pathology. Postsurgical
(post-thyroid unilateral lobectomy) FTC and FTA manage-
ment algorithms are different: only cancer patients require
completion total thyroidectomy, adjuvant radioiodine
treatment, and long-term follow-up. The histological
diagnosis of FTC remains a challenge for pathologists,
as the diagnostic criteria of FTC, namely capsular invasion
or angioinvasion, are prone to serious inter-observer vari-
ability [1]. Thus, the discrimination of FTC from FTA is
an important clinical problem, particularly for minimally
invasive cases, and depends on the number of serial
sections and tumour regions examined [2].
Several mutations play an important role in the biology
of follicular tumours, such as paired box gene 8 (PAX8)/
peroxisome proliferator-activated receptor gamma (PPARG)
translocation and RAS point mutations. The first one
occurs in 35–47% of FTC and up to 13% of FTA [3-5],
the second occurs in approximately 20–50% and 19% of
FTC and FTA, respectively [6-9].
Numerous single immunohistochemical markers have
been proposed, and the most widely accepted single protein
that improves diagnostic accuracy is galectin 3, even in the
case of minimally invasive follicular carcinoma [10].
Obviously, immunohistochemical panels can be extended
by including other proteins e.g., cytokeratin 19 or p27 [11].
Many other potential markers have been considered, such
as HBME-1, extracellular matrix metalloproteinase inducer
(EMMPRIN), growth arrest and DNA damage-inducible
gene 153 (GADD153), thyroid transcription factor 1
(TFF-1), Ki-67, p63, and p53 [12-15], but the conclusions
are limited by the relatively small size of tested populations.
Alternatively, the FTC and FTA differentiation problem
was investigated in several miRNA-profiling studies. Some
miRNAs are described as sensitive biomarkers of malignant
and benign follicular thyroid tumours [16-18], but the
overlap of differentiating miRNAs pointed out in these
studies is limited.
A number of attempts have been made to improve the
molecular diagnosis of FTC using specific mRNA sig-
natures of malignant follicular tumours [19-26]. The
most promising of these, by Borup and co-workers [19]
was based on a 40-sample microarray dataset and led
to the delineation of a 76-gene signature, which was highly
sensitive and specific both for their own dataset and when
tested with 2 previously published microarray datasets
[21,24]. Simultaneously, a recent publication by Chudova
et al. proposed a 167-gene classifier that was able to
diagnose thyroid nodules with indeterminate cytology
[27]. Although the classifier was trained on various types
of thyroid benign and malignant nodules, the prospective
multicentre validation study showed good specificity forfollicular thyroid nodules [28]. The proposed predictors
might be an important step to increase the effectiveness of
thyroid nodule diagnosis. The vast majority of recent
studies have concentrated on preoperative differential
diagnosis [26,28], with molecular tests applied to fresh-
frozen material with an aim to translate it into fine-needle
aspiration biopsy specimen testing. This is evidently very
important in the context of preoperative diagnosis, but it
may not be the most efficient method for direct applica-
tion to the analysis of formalin-fixed paraffin-embedded
(FFPE) samples at the mRNA level, which in our opinion
may aid postoperative differential diagnosis in controversial
cases. In this study, we aimed to combine the gathered
knowledge about the transcriptomes of FTC and FTA to
derive a novel classifier of thyroid follicular malignancy
applicable to FFPE material.
We therefore used the aforementioned available dataset
of Borup et al. for gene pre-selection, further selected genes
and trained the classifier on very carefully selected FTC
and FTA samples, and verified the classifier by real-time




Tumour samples for microarray analysis (fresh-frozen [FF]
material) were derived from 27 FTC (median age, 68 years)
and 25 FTA (median age, 47 years) patients treated by
thyroidectomy in Polish and German centers. The study
was approved by the local ethics committees of the MSC
Memorial Cancer Center and Institute of Oncology
(Gliwice, Poland), University of Leipzig (Leipzig, Germany),
University of Halle (Halle, Germany), and Mainz University
Hospital (Mainz, Germany) and informed consent was
obtained from all the patients.
Tumour samples for further validation (FFPE blocks)
were derived from 31 FTC patients (median age of patients,
61 years) and 40 FTA patients (median age, 49 years). All
patients were treated by thyroid surgery at MSC Memorial
Cancer Center and Institute of Oncology, Gliwice Branch,
and samples were subjected to routine histopathological
examination at the Department of Pathology between
2006 and 2010.
Microarray analysis
To obtain the highest possible level of adequacy for
histopathological diagnosis, samples containing enough
tissue material were subjected to independent and blinded
review by 2 thyroid pathology experts (S.H. and D.L.).
Only samples with full assessment and concordant
diagnoses from both pathologists were selected for the
training dataset (hereafter “training dataset B”), which
included 13 FTC and 13 FTA samples. The remaining
samples were used as an independent set of samples
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dataset D (Table 1), in which the initial clinical diagnosis
was used to describe the sample. The term “training
dataset” indicates the sample group used to build the gene
classifier and the term “testing dataset” indicates the sample
group used to test its performance.
RNA for microarray analysis was isolated using the
RNeasy Mini kit (Qiagen, Hilden, Germany) after tumour
content verification of the specimen by a pathologist. The
standard Affymetrix microarray protocol was carried out,
and samples were hybridized with the HG-U133 Plus 2.0
microarray. Microarray data analysis was performed in an
R/Bioconductor environment. Datasets were pre-processed
using the GC Robust Multiarray Average (GCRMA)
method [29]. The classifier was developed using the CMA
package [30]. Detailed methods are described in supple-
mental information (Additional file 1).
Validation experiment in FFPE samples
Blocks with sufficient tumour tissue in the specimen
(approximately 80%) were selected. RNA was isolated
using the FFPE RNeasy Mini Kit (Qiagen) from 5 slices
of paraffin blocks selected by a histopathologist. Details
are provided in Additional file 1.
Real-time quantitative PCR (qPCR) was carried out
for 8 genes selected from the training dataset: carbonic
anhydrase IV (CA4), engulfment and cell motility 1
(ELMO1), endomucin (EMCN), inter-alpha-trypsin inhibitor
heavy chain family, member 5 (ITIH5), potassium voltage-
gated channel, shaker-related subfamily, beta member
1 (KCNAB1), low density lipoprotein receptor-related pro-
tein 1B (LRP1B), pleckstrin homology domain containing,
family G (with RhoGef domain) member 4B (PLEKHG4B),
and solute carrier organic anion transporter family,
member 2A1 (SLCO2A1). PCR amplification was performed
with Universal Probe Library fluorescent probes (Roche,
Basel, Switzerland) and a 5′-nuclease assay, starting with
200 ng of total RNA. Normalization was carried out inTable 1 Description of datasets analyzed in the study






Borup et al. microarray dataset A 18 22 [19]
Training microarray dataset B 13 13 this study
Validation qPCR dataset C 31 40 this study
Validation microarray dataset D 14 12 this study
Weber et al. validation microarray
dataset E1
12 12 [24]
Hinsch et al. validation microarray
dataset E2
8 4 [21]
Total 96 103the GeNorm application [31]. Details of the methods
are provided in Additional file 1.
External microarray data and analysis pipeline
Three microarray datasets were downloaded from gene
expression repositories: the datasets of Borup et al.
(dataset A, 22 FTA and 18 FTC), Weber et al. (testing
dataset E1, 12 FTA and 12 FTC), and Hinsch et al. (testing
dataset E2, 4 FTA and 8 FTC). Details are provided in
Table 1 and in Additional file 1.
Dataset A was initially used for gene pre-selection.
Further selection of genes and training of the classifier
was carried out on dataset B (13 FTA and 13 FTC). The
obtained classifier was tested in a group of independent
new FFPE samples analyzed by qPCR (dataset C, 40 FTA
and 31 FTC). Additional testing was carried out on micro-
array datasets D (our own samples, fresh-frozen, 12 FTA
and 14 FTC) and the publicly available microarray datasets
E1 and E2. In total, 199 thyroid samples were analyzed
(123 of our own samples and 76 publicly available samples).
The clinical characteristics of all specimens used in the
analysis is presented in Table 1 and the analysis pipeline
is described in Figure 1.
Classifier construction and validation
Genes that exhibited significant differences between FTC
and FTA were pre-selected from dataset A. The selection
criteria were as follows: Student’s t-test (with equal variances
assumed), non-corrected p-value <0.0005 (<0.09 when the
p-value was corrected for multiple comparisons using
the false discovery rate method), mean gene expression >5
in either the FTC or FTA group, and an absolute log ratio
between the groups >1.5. Transcripts not fully annotated
were filtered out. When more than one probe set per
transcript was found, the probe set with the lowest p-value
was selected.
Based on the subset of pre-selected genes, further gene se-
lection using the Student's t-test (equal variances assumed),
and classifier training were carried out on dataset B.
Diagonal linear discriminant analysis (DLDA), a simple
and reliable method based on linear combinations of genes,
was chosen as the classification engine. However, other
more sophisticated methods of classification were also
used for comparison. Details of the analysis are provided
in Additional file 1. The accuracy of the classification
was assessed on dataset B using 10-fold cross-validation,
repeated 10 times.
The 5-gene classifier was validated by qPCR on dataset C.
First, the normalized expression data were log2-transformed.
Then, the classifier performance was assessed using leave-
one-out cross-validation (LOOCV; in each iteration, the
DLDA classifier was trained on n-1 samples and tested
on the remaining one). All 5 genes (validated by qPCR,
details in results) from dataset C were used in each iteration
Dataset A:
selection of 99 significant genes
Dataset B:
further selection of 8 genes and classifier 
cross-validation
Dataset C:
- expression analysis of 5 amplifiable genes
- cross-validation of the 5-gene classifier
- Roc curve analysis
Datasets D, E1, and E2:
Testing of the 5-gene classifier on microarray 
datasets
Collection of datasets for classifier training: 
- dataset A: external microarray data
- dataset B: own microarray data
Collection of datasets for classifier validation: 
- dataset C: FFPE samples for qPCR
- dataset D: own microarray data
- dataset E1, E2: external microarray data
Figure 1 Analysis pipeline. First, datasets were collected. Second,
the micorarray dataset A was analyzed and 99 genes were selected.
Third, the microarray dataset B was analyzed for further selection of
8 genes and classifier cross-validation. Next, qPCR dataset C was
analyzed in order to validate the classifier. Finally, public datasets D,
E1 and E2 were analysed to test the classifier.
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validation loops.
Dataset C was also used to create a receiver operating
characteristic (ROC) curve and to assess the diagnostic
efficacy of the classifier. In the leave-one-out loop, for
each sample, we calculated the probability that the sample
belongs to the FTC class. Varying the threshold for the
probability, the ROC curve was plotted.
An additional validation of the 5-gene classifier was
performed using microarray data (datasets D, E1, E2).
Both training dataset B and testing dataset D containedmicroarrays of the same type. Therefore, the final classifier,
which had been trained on dataset B, was directly tested
on dataset D. This approach was not possible for testing
datasets E1 and E2 as they contained different microarray
types. Therefore, LOOCV was used to assess the accuracy
of the classifier on those 2 datasets. In all validation steps,
only 5 genes amplified by qPCR were analyzed in the
microarray test datasets and no further gene selection
was used in the cross-validation loops.
Comparison of the classifiers
To compare the 5-gene classifier developed by us to other
published classifiers (the 76-gene classifier developed by
Borup et al. [19], 3-gene classifier developed by Weber
et al. [24], and 5-gene classifier developed by Foukakis
et al. [32]), we calculated the accuracies of those classi-
fiers in 4 different datasets: dataset B (our own), dataset
D (our own), dataset E1 [24], and dataset E2 [21].
Borup’s classifier was originally created on dataset A and
was based on 76 differentially expressed genes and the
SVM method with a radial kernel. To calculate its accuracy
on dataset B, we performed a 10-fold cross-validation of
such a classifier with a fixed list of 76 genes. To calculate
its accuracy on dataset D, we trained this classifier on
dataset B and tested it on dataset D. The accuracy of this
classifier on datasets E1 and E2 had already been reported
by Borup et al. and we used those values for comparison.
To calculate the accuracies of the classifiers developed
by Weber and Foukakis, we applied a DLDA classification
method. Analogous to the analysis above, to calculate the
accuracies of these classifiers on dataset B, we performed
a 10-fold cross-validation. To calculate their accuracies
on dataset D, we trained those classifiers on dataset B
and tested on dataset D. To calculate their accuracies
on dataset E1 and E2, we performed LOOCV analysis.
The accuracy of the 5-gene DLDA classifier on dataset
B was calculated by 10-fold cross-validation (genes were
selected by t-test). The calculation of the accuracy of our
classifier on datasets D, E1, and E2 is described above.
Results
Developing a robust classifier for FTC and FTA
differentiation
Because we aimed to obtain the most robust classifier
possible, and had access to 2 reliable datasets (our own
dataset with 26 samples [training dataset B] and the
dataset of Borup et al. with 40 samples [dataset A]), we
decided to use both of them sequentially for classifier
construction. First, from dataset A (large enough to
represent the variability of FTC) we selected 99 genes
with high significance and large magnitude of difference
(see Methods; the genes are listed in Additional file 2,
and the raw expression values of these genes in dataset
B are attached in Additional file 3). Second, based on
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diagnosis verification for each sample, based on the
consensus diagnosis of 2 independent histopathologists)
to build the classifier.
Cross-validation revealed that for the majority of classifi-
cation engines used, there was no meaningful increase in
multigene classifier accuracy, when more than 20 genes
were used within the preselected dataset of 99 genes.
(Additional file 1: Figure A). In an attempt to create a classi-
fier of low complexity and due to the material limitation,
we decided to validate only 8 genes, which provided almost
the same accuracy as that for a larger number of genes: 80%
and 84% accuracies for the 8-gene and 45-gene classifiers
(the one with maximal accuracy), respectively (Table 2).
For the classifier, we selected 8 transcripts that were
most significant in the analysis of 99 preselected genes
on dataset B: CA4, ELMO1, EMCN, ITIH5, KCNAB1,
LRP1B, PLEKHG4B, and SLCO2A1. The classifier built on
these genes was referred to as the 8-gene classifier. Al-
though we did not use information regarding the direction
of the gene expression change, all of these most significant
genes were downregulated in FTC. Detailed information
about the significance of these genes in all the datasets used
in the paper is included in Additional file 4.
Classifier testing on FFPE material and qPCR
We assessed the expression of all the 8 selected genes in
serial dilutions of calibrator RNA (mixture of excellent
quality RNA from FTA and FTC). Because of the poor
amplification of LRP1B, the gene was excluded from further
analysis (insufficient qPCR efficiency). Next, the genesTable 2 Performance measures of classifiers in different datas
Dataset (origin,
method of analysis)
Method Accuracy (%) PPV
B (own, microarray) DLDA classification based on
the 8 best genes chosen from
99 preselected ones.*
80 82
DLDA classification based on
45 (optimal number) best
genes chosen from 99
preselected ones.*
84 85









D (own, microarray) 5-gene DLDA classifier trained
on dataset B, tested on D
73 77
E1 (Weber et al.
microarray)
5-gene DLDA classifier.** 92 100
E2 (Hinsch et al.
microarray)
5-gene DLDA classifier.** 83 100
Accuracy, proportion of all samples that are correctly classified; PPV, positive predic
diagonal linear discriminant analysis; CI, confidence interval. *Performance assessed
leave-one-out cross-validation.of the 8-gene classifier were analyzed in test dataset C
(40 FTA and 31 FTC samples, RNA from FFPE blocks).
CA4 and PLEKHG4B did not amplify sufficiently in
FFPE samples (CA4 was amplified in 4 FTA and none of
the FTC samples, and PLEKHG4B in 3 FTAs and 1 FTC
samples; data not shown). This was probably due to the
low constitutive expression of these genes or their high
susceptibility to degradation (Additional file 1: Figure C).
To verify this, we evaluated the expression of these genes
by transcriptome sequencing of 2 FTCs and noted that
LRP1B, CA4, and PLEKHG4B exhibited low abundance in
FTC, compared to other genes (Additional file 1: Figure D).
Considering the poor amplification of the 3 genes, we
decided to proceed with the 5-gene classifier.
We confirmed that ELMO1, EMCN, ITIH5, KCNAB1,
and SLCO2A1 were downregulated in follicular carcinoma
compared to adenoma (Figure 2). The statistical signifi-
cance of the differences for all 5 transcripts was assessed
using the Mann–Whitney test. The results were significant
for all of them when no correction for multiple comparison
was used (p-value < 0.05), and for 4 of them (except ITIH5)
when the Bonferroni correction was used (Table 3).
We tested the final 5-gene classifier on the qPCR/FFPE-
derived test dataset C using a cross-validation approach
and obtained a classification accuracy of 72%, sensitiv-
ity of 72%, specificity of 71%, positive predictive value
(PPV) of 72%, and negative predictive value (NPV) of
67% (Table 2). Given that both PPV and NPV depend
on the composition of the dataset, we also calculated
the positive and negative likelihood ratios, which were
2.58 and 0.4, respectively.ets
(%) NPV (%) Sensitivity (%) Specificity (%) Prevalence
of FTC in
dataset (%)
78 76 83 50










88 90 55 44
69 71 75 54
86 83 100 50
67 75 100 67
tive value; NPV, negative predictive value; SVM, support vector machines; DLDA,

















































































Figure 2 Boxplots for the validated genes (ELMO1, EMCN, ITIH5, KCNAB1, and SLCO2A1). All genes were under-expressed in follicular
thyroid carcinoma (FTC) compared to follicular thyroid adenoma (FTA). All p-values were calculated using Mann–Whitney U test. The boxplots
show following values: median: middle line; 25–75 percentile: box; non-outlying range: whiskers; outliers: circles; extreme values: stars.
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ficity as equally important. For diagnostic selection
applications, however, maximizing sensitivity could be
of greater importance, even if that decreases specifi-
city. To analyse this aspect in-depth, we used the ROC
curve. By shifting the 5-gene classifier probability
threshold from 0.50 to 0.12, we were able to achieve a
sensitivity of 90%, with some decrease in specificity
(55%), and in the overall accuracy of the test (70%)
(Table 2, Figure 3).
Classifier testing on microarray datasets
The 5-gene classifier was further tested on 3 microarray
datasets: D, E1, and E2. The classifier was trained on datasetTable 3 Results for the 8 genes included in the classifier and
Gene Signal log ratio (FTC vs. FTA)
Dataset A Training dataset B Validation dataset C (F
ELMO1 −2.15 −2.36 −0.98
EMCN −1.94 −2.25 −1.17
ITIH5 −1.51 −1.98 −0.38
KCNAB1 −2.45 −3.35 −1.67




Log ratios of the 8 genes from microarray training datasets A and B, and validation
validated with qPCR are in bold.B and tested on dataset D, resulting in an accuracy of 73%.
Cross-validation of the classifier on datasets E1 and
E2 provided accuracies of 92% and 83%, respectively
(Table 2). These results further confirmed the reliability
of the classifier.
Comparison of the classifiers
We compared our simple 5-gene signature developed
in combined analysis of dataset A and B to the complex
76-gene signature developed by Borup et al. on dataset A.
We also compared our signature to the other classifiers,
which are also composed of a small number of genes
[24,32]. The accuracies of these classifiers, calculated on
4 datasets, are included in Table 4.chosen for qPCR validation on FFPE samples
Non-corrected p-value Bonferroni-corrected p-value









dataset C (qPCR), are presented. Mann–Whitney U test results for genes
Figure 3 ROC curve for the DLDA classifier that was
cross-validated on the dataset C. The circle marks the classifier with
a cut-off of 0.5 (specificity = 71%, sensitivity = 72%). The star marks
the classifier with a cut-off of 0.12 (specificity, 90%; sensitivity, 55%).
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Although follicular tumours are routinely diagnosed
post-surgically by classic histological criteria (tumour
capsule infiltration and/or angioinvasion), this field of
pathology is facing numerous challenges. These problems
were recognized early but are still not fully resolved. A
study from 1978 in Scandinavia has shown observer
disagreement of nearly 30% when examining follicular
carcinoma [33]. A report of agreement between 5 patholo-
gists diagnosing follicular thyroid tumours reported their
final consensus diagnosis in the range of 0.11-0.69 [1]. The
inter-observer agreement for FTC diagnosis in that paper
was estimated to 0.23, with large intra-observer variability
(0.68) [1]. Similar data were obtained by our group [34].
This stresses the need for extensive training of pathologists
involved in the diagnosis of follicular tumours, and the
importance of reference centers, but also points to the
necessity for tools that can improve pathologist accuracy.
When mining for novel molecular markers, it is important
that a consensus diagnosis by experienced pathologists be
used, as was done in our work.Table 4 Accuracy comparison for various classifiers
Classifier description Accuracy on dataset B Accuracy on
76-gene Borup's classifier 81% 81%
5-gene own classifier 77% 73%
3-gene Weber's classifier 77% 50%
5-gene Foukakis classifier 77% 61%
*Potentially overfitting (tested on the set from which it was developed).A number of gene expression profiling studies have
attempted to identify transcripts that are differentially
expressed between FTA and FTC [19-25]. However, none
of these studies resulted in a simple, efficient gene signature
that was applicable in clinical practice.
Recently, a promising gene expression classifier based
on 167 genes was created [27] and validated [28] in a large
multicentre trial. It was used for the discrimination be-
tween benign and malignant thyroid nodules that can-
not be determined by cytology. It achieved a sensitivity
of 92% and specificity of 52%, which is similar to our
results (sensitivity 90% and specificity 55%). While these
studies as well as other ones [28,35] lead towards a
classifier applicable to fine-needle aspiration biopsy
material, our approach is, in fact, different from these
other published reports. We aim to support the diagnosis
of post-thyroidectomy FFPE material carried out by routine
histopathology with additional mRNA-based markers.
Such a tool could be used as a pre-selection test to identify
tumours that need meticulous histopathological evaluation.
The genes selected in our study are differentiating in
degraded mRNA specimens from FFPE blocks, and
thus might potentially serve as a molecular indicator of
malignancy. Both approaches (preoperative small sample
cytology molecular testing [28] and post-operative whole
section FFPE-based analysis, as proposed here) are in
fact complementary and might be applied sequentially
to provide the optimal final diagnosis.
In our opinion, it is necessary that the classifier be
limited in the terms of genes tested, as cost-effectiveness
issues may hamper the clinical application of multigene
signatures; thus, selecting the optimal panel of markers
for further testing is of utmost importance, especially from
the perspective of health systems not reimbursing the cost
of complex genomic diagnostic methods.
One of the important limitations of many previous
studies concerning FTC/FTA differences is their relatively
small sample size. To our knowledge, in all microarray
studies published before 2010, the number of follicular
tumours ranged from 7 to 28 [20,22]. The Borup et al.
study, published in 2010, was based on a dataset of 40
follicular tumours, the largest non-custom microarray
dataset of follicular tumours to date. Thus, the gene pre-
selection in our study was based on a re-analysis of the
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exhibits accuracy comparable to that obtained using the
large, 76-gene classifier of Borup et al. On 2 of 4 datasets
used for comparison, it gave the same accuracy as the
large classifier, and in the other 2, the loss of accuracy
was lower than 10%. When compared to other classifiers
with a similar number of genes (3-gene classifier of Weber
and 5-gene classifier of Foukakis), our classifier gives better
accuracies on validation datasets. Our test set (dataset C),
derived from FFPE samples and analyzed using qPCR,
reproduces cases obtained in a routine setting. The classi-
fier accuracy obtained on this dataset is 72%, with a sensi-
tivity of 71% and specificity of 72%. For the detection of
cancer, the sensitivity is of utmost importance; shifting the
test threshold gives a sensitivity of 90%, with an acceptable
specificity of 55%. This approach seems justified, as the
gain in FTC diagnosis sensitivity would outweigh the drop
in specificity via careful histopathological assessment.
From the initial 8-gene classifier, 3 genes: CA4, LRP1B,
and PLEKHG4B, could not be amplified with qPCR,
probably due to their low expression in FFPE specimens.
The remaining 5 genes, positively validated in our analysis,
are downregulated in FTC compared to adenoma. ELMO1,
EMCN, KCNAB1, and SLCO2A1 are plasma membrane
components and ITIH5 is an extracellular matrix (ECM)
component. Some of these proteins exhibit functional
similarities: SLCO2A1 and KCNAB1 exhibit transporter
activity [36,37], and ELMO1, EMCN, and ITIH5 are
involved in cell movement and ECM stability [38-40].
Some of the genes from our 5-gene classifier have already
been mentioned in other studies of high-throughput gene
expression analysis of follicular tumours. ITIH5, KCNAB1,
and SLCO2A1 are mentioned in the Borup et al. study.
Besides, ELMO1 is differentially expressed in Barden et al.
[41] and KCNAB1 is differentially expressed in 2 other
papers by Takano [23] and Weber [24], respectively.
There are some potential limitations to our study. The
most important issue, applying both to our analysis as
well to all other studies carried out to date, is that we do
not understand the reason for sample misclassification.
Are the misclassified samples the same that would be
misclassified by histopathologists? The excellent prognosis
of follicular cancer treated with adequate surgical and
adjuvant therapy makes this assessment difficult, given that
patients exhibiting disease recurrence or dissemination
initially or during follow up are relatively rare. This issue
will be addressed in future studies, preferably using gene
expression profiling of FTCs with metastases or local recur-
rence. We also cannot exclude the possibility that the rea-
son for incorrect classification of some samples is that the
signal from a small amount of neoplastic tissue might be
dominated by the surrounding normal thyroid tissue.
Because routine diagnostic applications of the test is
our goal, we did not apply any methods, such as paraffinslide micro dissection, to enrich the tumour content of our
samples, as these methods are difficult to apply in the
clinical setting. We believe that our signature is useful, as it
was constructed using 2 large datasets and validated on an
independent dataset using a different method. Although it
is not efficient enough to be used as a clinical diagnostic
test by itself, it would improve the process of diagnosis
[42]. It is also a step towards developing a highly powerful
classifier, as each microarray dataset generated and analyzed
improves our understanding of gene expression differences
between different types of follicular tumours. Additional
studies also should be undertaken to elucidate the mo-
lecular and clinical aspects of the discovered markers.
We must stress that the problem of FTC and FTA
differentiation has also been investigated by several
miRNA-profiling studies. miRNAs are known to be a
good disease markers, and can be easily detected in frozen
tissues, paraffin blocks (FFPE), fine-needle aspiration
biopsies (FNAB), or even serum [43]. Some miRNAs are
described as sensitive biomarkers of malignant and benign
follicular thyroid tumours [16-18]. In future, a possible
FNA or FFPE-block test might combine degradation-
resistant mRNA markers or protein markers and a panel of
miRNAs to provide optimal analytical parameters.
Conclusions
In summary, we developed a simple 5-gene classifier that
can distinguish FTC from FTA with good accuracy. It is
based on the 2 largest FTC-FTA microarray datasets
and was validated on an independent FFPE sample set,
with a potential sensitivity of up to 90%. In future, such
a molecular test may serve as an important tool for
assisting pathologists in cases of thyroid follicular neo-
plasms where a clear clinical decision cannot be made
based on histopathology.Additional files
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